Epsilon Healthcare has more than doubled its revenue to $7.59 million in the first half of 2026, cutting its net loss by 65% as its CDMO and pharmacy segments gain traction.
- Revenue surged 123% to $7.59 million
- Net loss reduced by 65% to $726,000
- Positive EBITDA of $255,000 achieved
- New unsecured debt facility of $1.72 million established
- Share register streamlined, reducing shareholder count
Revenue More Than Doubles on CDMO and Pharmacy Growth
Epsilon Healthcare Limited (ASX:EPN) has posted a striking turnaround in its financial performance for the half year ended 30 June 2026. Revenue climbed 123% to $7.59 million, propelled by robust growth in its Contract Development and Manufacturing Organisation (CDMO) segment and the expansion of its Epsilon Pharmacy business. This growth helped reduce the company's net loss by 65%, from $2.07 million in H1 2025 to $726,000.
The CDMO segment, based in Southport, Queensland, saw revenue jump 120% year-on-year, reflecting renewed client activity and new commercial opportunities both domestically and internationally. Meanwhile, the pharmacy and clinic operations also contributed strongly, broadening the company's revenue base and underpinning its emerging business model.
Positive EBITDA and Cash Flow Signal Operational Progress
Beyond topline growth, Epsilon Healthcare achieved a positive EBITDA of $254,869 for the period, a marked improvement from the prior year's negative EBITDA of $2.3 million. The company also generated net operating cash inflows of $1.03 million, reversing the cash burn of the previous corresponding period. These metrics highlight a more disciplined cost base and improved operational efficiency.
Cost savings have been aided by the elimination of approximately $1.16 million in non-recurring expenses related to prior year voluntary administration, legal, and accounting fees. This has provided a cleaner financial footing to support sustainable growth moving forward.
Capital Management and Share Register Streamlining
In a bid to improve administrative efficiency and reduce costs, Epsilon Healthcare completed a small holding share sale facility in June 2026. This initiative reduced the shareholder count from about 7,063 to 1,688, with gross proceeds of roughly $490,000 distributed to participating shareholders. The shares sold were acquired by existing shareholders, consolidating the register.
On the funding front, the company terminated its previous $2 million promissory note facility and replaced it with a new unsecured loan facility of up to $1.72 million, maturing at the end of 2027. No drawdowns had been made on this facility as of the report date, but it provides additional capital flexibility to support ongoing expansion and potential revenue-accretive acquisitions.
Segment Performance and Financial Position
Segment analysis shows the CDMO unit generated $6.32 million in revenue with a positive EBITDA of $968,000, while the pharmacy segment reported nearly $1 million in revenue and an EBITDA profit of $121,000. The telehealth medical practice segment continued to operate at a loss, reflecting investment in growth initiatives.
At balance date, Epsilon Healthcare held $1.29 million in cash and cash equivalents and reported net assets of $3.88 million, up from $1.91 million at the start of the year. The company’s tangible net assets per share nearly doubled to 0.98 cents, indicating improved shareholder value metrics.
Outlook Remains Focused on Sustainable Growth
Chairman Alan Beasley emphasised that the results mark a key milestone in Epsilon Healthcare’s transformation, with management intent on converting momentum into sustainable growth. The company will continue to deepen client relationships, develop new commercial opportunities, and pursue strategic initiatives to broaden its revenue base and strengthen its market position.
While the company remains in a net loss position, the combination of operational improvements, a more sustainable cost structure, and enhanced capital flexibility provide a platform for the next phase of development. The new unsecured debt facility and streamlined share register are tactical moves to support this trajectory.
Bottom Line?
Epsilon Healthcare’s strong H1 revenue surge and positive EBITDA signal a turning point, but the path to sustained profitability hinges on maintaining growth momentum and managing costs.
Questions in the middle?
- Will Epsilon Healthcare’s CDMO segment sustain its rapid growth amid competitive pressures?
- How quickly can the pharmacy and clinic operations scale to profitability?
- What impact will potential drawdowns on the new unsecured loan facility have on financial flexibility?